A Phase 1 interventional study of [14C]ABT-199 (GDC-0199) in Relapsed/Refractory Non-Hodgkin's Lymphoma, sponsored by AbbVie. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-13.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing venetoclax in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, 1 of them phase 3. venetoclax · Lymphoma, Non-Hodgkin.
Among the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, this one is the 22nd largest by enrollment, is one of 3 that started in 2014, is one of 15 in phase 1, and was the 6th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →3 of the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Melbourne Health · Sites in Australia
Ages 18–75
AbbVie · Sites in United States, Australia
Ages 18+ · Women only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 6 · Phase 3 2
First in 2011; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 25 across the 23 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 23 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
31 studies in Lymphoma, Non-Hodgkin by AbbVie: 1 open now, 5 under way, 1 of them phase 3. Of 23 finished, 7 (30%) have results posted.
Among the 31 studies in Lymphoma, Non-Hodgkin by AbbVie, this one is the 29th largest by enrollment, is one of 4 that started in 2014, is one of 19 in phase 1, and was the 17th registered.
AbbVie’s Lymphoma, Non-Hodgkin studies by the year they started, since 2006.
3 of the studies testing venetoclax in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05053659Paolo Caimi, MDLoncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma | 2026-11 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, from their registry updates:
Among AbbVie’s 31 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
A pharmacokinetic study to access how the body absorbs and removes ABT-199 in adults with Non-Hodgkin's Lymphoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with relapsed or refractory Non-Hodgkin's Lymphoma
Drug: [14C]ABT-199 (GDC-0199)
\[14C\]ABT-199 will be administered as a single oral administration
Maximum observed plasma concentration (Cmax) of ABT-199 and [14C]ABT-199
Time frame: For approximately 9 days following a single oral dose of [14C]ABT-199
Time to Cmax (Tmax) for ABT-199 and [14C]ABT-199
Time frame: For approximately 9 days following a single oral dose of [14C]ABT-199
Area Under the Time curve (AUC) for ABT-199 and [14C]ABT-199
The area under the exposure-time curve from time zero to Day 9 and time zero extrapolated to infinite time for single dose of \[14C\]ABT-199
Time frame: For approximately 9 days following a single oral dose of [14C]ABT-199
Number of subjects with adverse events
Adverse event monitoring, lab test assessment, physical exam and vital signs will be evaluated throughout the study.
Time frame: At each visit (daily for approximately the first 9 days)
Percentage of subjects with adverse events
Adverse event monitoring, lab test assessment, physical exam and vital signs will be evaluated throughout the study.
Time frame: At each visit (daily for approximately the first 9 days)
No study locations are listed for this record.
The record gives a start of Sep 2014, a primary completion of Sep 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax